Next Article in Journal
Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
Previous Article in Journal
Manipulation of Medicinal Products for Oral Administration to Paediatric Patients at a German University Hospital: An Observational Study
Previous Article in Special Issue
Ciprofloxacin Loaded Nanostructured Lipid Carriers Incorporated into In-Situ Gels to Improve Management of Bacterial Endophthalmitis
Open AccessArticle

Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production

1
Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de investigación Lascaray ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain
2
Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(6), 584; https://doi.org/10.3390/pharmaceutics12060584
Received: 16 May 2020 / Revised: 17 June 2020 / Accepted: 20 June 2020 / Published: 23 June 2020
(This article belongs to the Special Issue Ocular Drug Delivery: Present Innovations and Future Challenges)
One of the main challenges in gene therapy is the issue of delivery, and it is especially relevant for the success of gene therapy in the cornea. In the present work, eye drops containing biocompatible non-viral vectors based on solid lipid nanoparticles (SLNs) as gene delivery systems to induce the expression of interleukin 10 (IL-10) were designed to address the treatment of corneal inflammation. Two kinds of SLNs combined with different ligands (protamine, dextran, or hyaluronic acid (HA)) and formulated with polyvinyl alcohol (PVA) were prepared. SLN-based vectors were characterized in terms of size, adhesiveness, viscosity, and pH, before topical administration to wild type and IL-10 knock out (KO) mice. The formulations showed a homogenous particle size below 400 nm and a positive surface charge to favor bioadhesion; the incorporation of PVA improved the corneal penetration. After three days of treatment by topical instillation, SLN-based vectors mainly transfected corneal epithelial cells, HA-formulations being the most effective ones. IL-10 was capable of reaching even the endothelial layer. Corneal sections showed no histological change and formulations seemed to be well tolerated after repeated topical administration. These promising results highlight the possible contribution of non-viral gene augmentation therapy to the future clinical approach of corneal gene therapy. View Full-Text
Keywords: gene therapy; solid lipid nanoparticles; polyvinyl alcohol (PVA); corneal inflammation; interleukin-10; transfection; IL-10 knock out mice; topical administration gene therapy; solid lipid nanoparticles; polyvinyl alcohol (PVA); corneal inflammation; interleukin-10; transfection; IL-10 knock out mice; topical administration
Show Figures

Graphical abstract

MDPI and ACS Style

Vicente-Pascual, M.; Gómez-Aguado, I.; Rodríguez-Castejón, J.; Rodríguez-Gascón, A.; Muntoni, E.; Battaglia, L.; del Pozo-Rodríguez, A.; Solinís Aspiazu, M.Á. Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production. Pharmaceutics 2020, 12, 584.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop